Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have received an average rating of “Hold” from the four ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $9.30.

A number of analysts recently issued reports on the stock. TD Cowen began coverage on shares of Valneva in a report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a research report on Monday, June 1st.

Hedge Funds Weigh In On Valneva

A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd purchased a new position in Valneva during the fourth quarter worth approximately $94,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva in the fourth quarter valued at approximately $44,000. JPMorgan Chase & Co. acquired a new position in shares of Valneva during the 3rd quarter worth approximately $124,000. Finally, Marex Group plc acquired a new position in shares of Valneva during the 2nd quarter worth approximately $64,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Stock Down 3.0%

Valneva stock opened at $6.75 on Tuesday. The business’s 50-day simple moving average is $5.43 and its two-hundred day simple moving average is $6.80. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The company has a market cap of $640.51 million, a PE ratio of -3.20 and a beta of 1.77. Valneva has a fifty-two week low of $4.75 and a fifty-two week high of $12.23.

Valneva (NASDAQ:VALN) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The company had revenue of $39.37 million during the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. Equities analysts anticipate that Valneva will post -1.27 EPS for the current year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.